Augmented Momentary Personal Ecological Risk Evaluation
The goal of this intervention study is to co-design and test an Ecological Momentary Assessment (EMA) prototype tool with young adults aged 16-30 experiencing suicidality to see if it is an acceptable and usable clinical tool for risk management. The main study aims are: * To co-design a prototype EMA suicide risk moni
| Condition(s) | Suicidal Ideation, Self Harm |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this intervention study is to co-design and test an Ecological Momentary Assessment (EMA) prototype tool with young adults aged 16-30 experiencing suicidality to see if it is an acceptable and usable clinical tool for risk management. The main study aims are: * To co-design a prototype EMA suicide risk monitoring system with patients and health care provider input using Human Centered Design (HCD) methods. * To test the developed EMA protype with providers and their young adult patients aged 16-30 experiencing suicidality to determine if the EMA prototype is an acceptable and usable clinical tool. Young adult participants receiving care for active suicidal ideation will * Download and use the EMA prototype for a total of two months. * Complete 3 online surveys at 0, 1 and 2 mon |
| Who can participate | Inclusion Criteria: * Young adults (age 16-30 years) * Receiving care at University of Washington Primary Care for suicidal ideation as determined by Electronic Health Record problem list or PHQ-9 suicide risk item \>0 in previous year and/or recent (past year) history of suicide attempt and/or active suicidal ideation. * Ability to consent to participate Exclusion Criteria: * Age \<16 or \>30, * Non-English speaking * No smart phone access * Any clinical medical/psychiatric condition, severity of that condition, or life situation that would compromise safe and voluntary study participation. |
| Ages | 16 Years to 30 Years |
| Sex | All |
| Lead sponsor | University of Washington |
| Locations | Seattle, Washington, United States |
| Start date | 2025-09-25 |
| NCT ID | NCT06704958 |
| Official listing | https://clinicaltrials.gov/study/NCT06704958 |